ACTG 359:SOFT GELATIN CAPSULE OF SAQUINAVIR W/ RITONAVIR OR NELFINAVI

仅限核心实验室-样品处理。HIV蛋白酶抑制剂是一类具有较强抗逆转录病毒活性的新型抗逆转录病毒药物。在长达一年的时间里，服用齐多夫定经验的患者与齐多夫定和拉米夫定联合服用依地那韦，可以将大约85%的患者的病毒载量降低到每毫升500份以下。这使得至少15%的患者尽管使用了含有吲哚那韦的联合疗法，但病毒载量仍在每毫升500个拷贝以上。对于那些经历过病毒载量丰富或从未经历过病毒载量降至每毫升500份以下的人来说，对于服用含有吲哚那韦的联合方案的人来说，最佳的治疗方案是未知的。这项研究正式测试了沙奎那韦软胶囊与利托那韦或奈非那韦以及地拉韦丁和/或阿德福韦酯的组合在一组有indinavir经验和显著病毒载量水平的受试者中的活性。

CORE LAB ONLY - SAMPLE PROCESSING. The HIV protease inhibitors are a new class of antiretroviral agents with potent activity. Indinavir, given to zidovudine-experienced patients in combination with zidovudine and lamivudine, reduced viral loads in about 85% of patients to less than 500 copies per milliliter for up to one year. This leaves at least 15% of patients who continue to have viral loads above 500 copies per milliliter despite the indinavir-containing combination regimen. The optimal therapy for a person on an indinavir-containing combination regimen whose experiences are abound in viral load or never experiences a decrease in viral load below 500 copies per milliliter is unknown. This study formally tests the activity of the soft gelatin capsule of saquinavir in combination with ritonavir or nelfinavir and combinations of delavirdine, and/or adefovir dipivoxil in a group of subjects with indinavir experience and significant viral load levels.